Drug intelligence / Profile preview

ZM012

Development stage: Preclinical
Lead developer: Zumutor Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ZM012 is a monoclonal antibody currently in the discovery stage of development by Zumutor Biologics Inc. for the treatment of lymphoma. Developed using the company's proprietary INABLR antibody discovery platform, ZM012 is designed as an immuno-oncology therapeutic that functions by simultaneously engaging a tumor-associated antigen (TAA) and a Natural Killer (NK) cell receptor. This dual-targeting mechanism is intended to modulate the tumor microenvironment by activating NK cells and directing their cytotoxic activity specifically against tumor cells. ZM012 is part of Zumutor's broader pipeline focused on novel NK cell-mediated immunotherapies.

Targets

MAGEA8 (Melanoma-associated antigen 8)NCR2 (Natural cytotoxicity triggering receptor 2)

Beyond the preview

Go deeper on ZM012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZM012.

Explore the full profile